Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

By Lamond Nathan   Skedgel Chris   Rayson Daniel   Lethbridge Lynn   Younis Tallal  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1115-1123

Springer Publishing Company

Access to resources Recommend Favorite

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite

Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer

By  

Acta Oncologica, Vol. 42, Iss. 1, 2003-01 ,pp. : 1-1

Informa Healthcare

Access to resources Recommend Favorite

Routine Histopathologic Characteristics Can Predict Oncotype DX^TM Recurrence Score in Subsets of Breast Cancer Patients

By Mattes Malcolm D.   Mann Justin M.   Ashamalla Hani   Tejwani Ajay  

Cancer Investigation, Vol. 31, Iss. 9, 2013-11 ,pp. : 604-606

Informa Healthcare

Access to resources Recommend Favorite

A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer

By El-mezayen Hatem   Metwally Fatheya   Darwish Hossam  

Tumor Biology, Vol. 35, Iss. 3, 2014-03 ,pp. : 2759-2767

Springer Publishing Company

Access to resources Recommend Favorite